Biocon is close to acquire a 70% stake in German pharmaceutical Company, AxiCorp GmbH for a consideration of €30 million. This will enable the marketing and distribution of a range of pharmaceuticals including generics, biosimilars, biologies and innovative pharmaceutical products in Germany and Europe.
AxiCorp is a specialized marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe. AxiCorp is ISO 9001 certified with a differentiated distribution model that is aligned to the radically altered way the German pharmaceutical market now functions.
An open label, multi-centric, placebo controlled, single ascending dose study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of IN105 under fed conditions in type II diabetic patients currently on Metformin therapy has been commenced at 5 investigation sites. The study is expected to be completed in August 2008 and will provide the data necessary to commence phase IIb clinical trials.
A Randomized, open label, four arms parallel phase II clinical study to evaluate the safety and efficacy of anti-CD6 monoclonal antibody (T1h mAb) in combination with methotrexate in patients with active rheumatoid arthritis has been initiated at 7 investigation sites.
Another phase II clinical trial to evaluate the safety, efficacy and pharmacokinetics of anti-CD6 monoclonal antibody (T1h mAb) in patients with active Psoriasis is also due to commence at 5 investigation sites. This has been designed as a single blind, randomized, multiple dose, multiple schedule, multi-centric, parallel study in patients with active moderate to severe Psoriasis, with independent blinded disease activity assessment, and quality of life metrics assessment. These clinical trials will enable Biocon to establish proof of concept for T1h and will add tremendous value to its licensing potential.
An open label, prospective, multi-centric study to evaluate the Safety And Efficacy of BIOMAb-EGFR (Nimotuzumab) as Induction and Maintenance Therapy in combination with Radiotherapy plus Temozolomide in Indian patients with Glioblastoma Multiforme is ongoing at 8 investigational sites across the country.
Another clinical trial designed as an open-label, randomized, comparative, multi-centric study to assess safety and efficacy of BIOMAb-EGFRTM (Nimotuzumab) in combination with chemotherapy versus chemotherapy alone in the treatment of patients with stage IIIB / IV non small cell lung cancer is also being initiated at 11 sites. The above clinical trials will enable Biocon's Oncotherapeutics division to expand its market share through label extensions.
Biocon has decided to split up its cardio-diabetes group by launching a stand alone cardiology division. This new division is being launched to focus on brand building for its flagship statin based product Statix as well as other products viz. Telmisat, Eptifibatide and its recombinant streptokinase product Myokinase. The cardiology market in India constitutes 10%.
The company made this announcement during the trading hours today, 22 April 2008
AxiCorp is a specialized marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe. AxiCorp is ISO 9001 certified with a differentiated distribution model that is aligned to the radically altered way the German pharmaceutical market now functions.
An open label, multi-centric, placebo controlled, single ascending dose study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of IN105 under fed conditions in type II diabetic patients currently on Metformin therapy has been commenced at 5 investigation sites. The study is expected to be completed in August 2008 and will provide the data necessary to commence phase IIb clinical trials.
A Randomized, open label, four arms parallel phase II clinical study to evaluate the safety and efficacy of anti-CD6 monoclonal antibody (T1h mAb) in combination with methotrexate in patients with active rheumatoid arthritis has been initiated at 7 investigation sites.
Another phase II clinical trial to evaluate the safety, efficacy and pharmacokinetics of anti-CD6 monoclonal antibody (T1h mAb) in patients with active Psoriasis is also due to commence at 5 investigation sites. This has been designed as a single blind, randomized, multiple dose, multiple schedule, multi-centric, parallel study in patients with active moderate to severe Psoriasis, with independent blinded disease activity assessment, and quality of life metrics assessment. These clinical trials will enable Biocon to establish proof of concept for T1h and will add tremendous value to its licensing potential.
An open label, prospective, multi-centric study to evaluate the Safety And Efficacy of BIOMAb-EGFR (Nimotuzumab) as Induction and Maintenance Therapy in combination with Radiotherapy plus Temozolomide in Indian patients with Glioblastoma Multiforme is ongoing at 8 investigational sites across the country.
Another clinical trial designed as an open-label, randomized, comparative, multi-centric study to assess safety and efficacy of BIOMAb-EGFRTM (Nimotuzumab) in combination with chemotherapy versus chemotherapy alone in the treatment of patients with stage IIIB / IV non small cell lung cancer is also being initiated at 11 sites. The above clinical trials will enable Biocon's Oncotherapeutics division to expand its market share through label extensions.
Biocon has decided to split up its cardio-diabetes group by launching a stand alone cardiology division. This new division is being launched to focus on brand building for its flagship statin based product Statix as well as other products viz. Telmisat, Eptifibatide and its recombinant streptokinase product Myokinase. The cardiology market in India constitutes 10%.
The company made this announcement during the trading hours today, 22 April 2008
0 comments:
Post a Comment